ClinicalTrials.gg
CompletedNCT00672282SPCG6Updated May 27, 2009

Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

A Phase 3 interventional study of Bicalutamide and Placebo in Non-Metastatic Prostate Cancer, sponsored by AstraZeneca. Completed at 54 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,218
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Enrollment
8th of 54
1,218 · median 53
Started
1995
with 2 others
Phase 3
21 of 55
1 open now
Registered
26th of 55
by date
Lead sponsor
8 of 55
AstraZeneca

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 8th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 1995, is one of 21 in phase 3, and was the 26th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

03

Conditions studied

  • Non-Metastatic Prostate Cancer

Browse trials for

Keywords

  • androgen antagonists
  • prostate neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of non- cancer of the prostate gland
  • Patient to be 18 years and above

Exclusion criteria

Exclusion Criteria:

  • Previous systemic therapy for prostate cancer
  • Previous history of another form of cancer (not prostate) within 5 years of study start.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,218 participants (actual)

Study arms

  • Placebo comparator
    A

    Drug: Placebo

  • Active comparator
    B

    Drug: Bicalutamide

Interventions

  • 150mg p.o. daily

    Also known as: Casodex

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Survival

    Time frame: Throughout study period

  2. Time to clinical progression

    Time frame: Throughout study period

Secondary outcomes

  1. Tolerability in terms of adverse events and laboratory parameters

    Time frame: Throughout study period

  2. Time to treatment failure

    Time frame: Throughout study period

  3. Prostate-specific antigen

    Time frame: Initial study period up to 2005 amended protocol

07

Study locations

54 sites
  • Research Site
    Aalborg, Denmark
  • Research Site
    Charlottenlund, Denmark
  • Research Site
    Esbjerg, Denmark
  • Research Site
    Frederiksberg, Denmark
  • Research Site
    Frederikssund, Denmark
  • Research Site
    Glostrup, Denmark
  • Research Site
    Herlev, Denmark
  • Research Site
    Holbuk, Denmark
  • Research Site
    Kobenhavn, Denmark
  • Research Site
    Nyk Bing Falster, Denmark
  • Research Site
    Odense, Denmark
  • Research Site
    Orhus, Denmark
  • Research Site
    Randers, Denmark
  • Research Site
    S Nderborg, Denmark
  • Research Site
    Helsinki, Finland
  • Research Site
    Joensuu, Finland
  • Research Site
    Kokkola, Finland
  • Research Site
    Kuopio, Finland
  • Research Site
    Lahti, Finland
  • Research Site
    Lappeenranta, Finland
  • Research Site
    Oys (oulu), Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Bergen, Norway
  • Research Site
    Bodu, Norway
  • Research Site
    Drammen, Norway
  • Research Site
    Fredrikstad, Norway
  • Research Site
    Harstad, Norway
  • Research Site
    Kristiansand, Norway
  • Research Site
    Lesund, Norway
  • Research Site
    Levanger, Norway
  • Research Site
    Lillehammer, Norway
  • Research Site
    Oslo, Norway
  • Research Site
    Porsgrunn, Norway
  • Research Site
    RUD, Norway
  • Research Site
    Stavanger, Norway
  • Research Site
    Strummen, Norway
  • Research Site
    Tromsu, Norway
  • Research Site
    Trondheim, Norway
  • Research Site
    Tunsberg, Norway
  • Research Site
    Goteborg, Sweden
  • Research Site
    Govle, Sweden
  • Research Site
    Helsingborg, Sweden
  • Research Site
    Hudiksvall, Sweden
  • Research Site
    Junkoping, Sweden
  • Research Site
    Kristinehamn, Sweden
  • Research Site
    Luleo, Sweden
  • Research Site
    Malmu, Sweden
  • Research Site
    Norrkoping, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Urebro, Sweden
  • Research Site
    Ustersund, Sweden
  • Research Site
    VoSTEROS, Sweden
  • Research Site
    Vostervik, Sweden
08

References and documents

Publications

  • Thomsen FB, Brasso K, Berg KD, Gerds TA, Johansson JE, Angelsen A, Tammela TL, Iversen P; Scandinavian Prostate Cancer Group. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. Ann Oncol. 2016 Mar;27(3):460-6. doi: 10.1093/annonc/mdv607. Epub 2015 Dec 17. PubMed 26681677 ↗
  • Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x. PubMed 22129214 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1995 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 6, 2008
Start
Oct 1995
CompletionActual
Aug 2008
Last update
May 27, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00672282
Lead sponsor
AstraZeneca
Collaborators
Scandinavian Prostate Cancer Group
First posted
May 6, 2008
Start date
Oct 1995
Completion
Aug 2008
Last update
May 27, 2009

Study contacts

Peter Iversen, MD
principal investigator · Department of Urology Rigshospitalet Copenhagen Denmark

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion